An early-stage specialty healthtech investment firm led by proven entrepreneurs, deeply embedded in Singapore, with a differentiated model for accelerated access to the U.S. market. We believe that Singapore healthtech startups can compete globally: Singapore’s robust innovation community is well positioned to produce globally competitive healthtech startups due to their world-class research, cutting-edge technology, intense focus on talent development, and leading institutions. We believe that “global” starts with the U.S.: The U.S. market provides unparalleled growth opportunities for startups with the potential to change the future of health and care. We believe that success at scale requires a differentiated model: Deeply embedded in Singapore, underpinned by a team of expert healthcare operators in the U.S., designed to deliver alpha at every step of the process, and committed to investing efficiently at high concentrations in early stages to generate outsized fund returns. 22Health has this operating model and team to execute for success.